# Aulos Bioscience Reports Phase 2 Imneskibart Data in Refractory Melanoma and Lung Cancer > Aulos Bioscience reported Phase 2 imneskibart data showing 9.1-month median PFS in checkpoint inhibitor-refractory melanoma and 5.8 months in NSCLC. - Published: 2026-11-06T14:19:56+00:00 - Section: Research & Clinical Trials - Author: News Desk - URL: https://newsforagent.com/news/2026-11-06/aulos-bioscience-imneskibart-phase-2-data - Source: [Business Wire](https://www.businesswire.com/news/home/20261106466970/en/) ## Key takeaways - The imneskibart triplet regimen in melanoma achieved a median PFS of 9.1 months and a 28% ORR among 18 response-evaluable patients. - The imneskibart doublet in melanoma delivered a 6.9-month median PFS and 29% ORR, including a complete response lasting more than 32 months. - In CPI-refractory adenocarcinoma NSCLC, the imneskibart triplet produced a 5.8-month median PFS, 21% ORR and 86% disease control rate. [Aulos Bioscience](https://akta.pro/company-profiles/0000pg8/aulos-bioscience) reported Phase 2 data on November 6, 2026 showing its lead antibody imneskibart produced a median progression-free survival of 9.1 months and a 28% objective response rate in checkpoint inhibitor-refractory melanoma. The results were presented in two posters at the Society for Immunotherapy of Cancer Annual Meeting in Phoenix, Arizona, [Business Wire](https://www.businesswire.com/news/home/20261106466970/en/) reported. Aulos Bioscience is a clinical-stage immuno-oncology company developing imneskibart (AU-007), an AI-designed monoclonal antibody that redirects IL-2 toward anti-tumor immune activation while avoiding regulatory T cell expansion and IL-2 toxicities. ## Imneskibart's Melanoma and Lung Cancer Results The melanoma triplet regimen of imneskibart plus low-dose subcutaneous aldesleukin and nivolumab achieved a median PFS of 9.1 months and a 28% ORR among 18 response-evaluable patients, including one confirmed complete response. The doublet regimen of imneskibart plus low-dose aldesleukin without nivolumab achieved a median PFS of 6.9 months and a 29% ORR, including a confirmed complete response lasting more than 32 months. Patients in the triplet cohort had received a mean of 2.7 prior lines of treatment and those in the doublet cohort a mean of 2.4 prior lines. In heavily pretreated patients with advanced adenocarcinoma NSCLC, the triplet regimen of imneskibart plus low-dose subcutaneous aldesleukin and avelumab achieved a median PFS of 5.8 months, a confirmed ORR of 21% and a disease control rate of 86%. Median overall survival had not been reached at a median follow-up of 10.6 months. Patients had received a mean of 2.6 prior lines of therapy. "We believe these are exceptional results for imneskibart in two of the most challenging populations in oncology – melanoma and NSCLC patients whose tumors have progressed despite multiple prior treatments," said Aron Knickerbocker, President and Chief Executive Officer of Aulos Bioscience. ## Aulos Bioscience's Funding and Merck KGaA Agreement According to akta.pro [company records](https://akta.pro/company-data), Aulos Bioscience has raised $60 million in total, comprising a $40 million Series A from Apple Tree Partners at founding in January 2021 and a $20 million Series A extension in August 2023 led by Apple Tree Partners. In November 2024 the company entered a clinical trial collaboration and supply agreement with Merck KGaA (Ares Trading S.A.) to evaluate AU-007 in combination with avelumab and low-dose aldesleukin in a Phase 2 NSCLC cohort. ## Earlier Imneskibart Presentations In May 2026, Aulos Bioscience announced positive Phase 2 data for imneskibart in doublet checkpoint inhibitor-refractory metastatic melanoma, to be presented at ASCO 2026, showing a 33% objective response rate and 67% disease control rate in 12 evaluable patients receiving the triplet regimen of imneskibart, low-dose subcutaneous aldesleukin and nivolumab, Business Wire Blog reported. In October 2026, the company announced two presentations of Phase 1/2 data for imneskibart at the SITC 2026 Annual Meeting, [FinancialContent Business Page](https://akta.pro/news-signals) reported. Later that month, Aulos Bioscience presented Phase 2 data for imneskibart with avelumab in checkpoint inhibitor-refractory adenocarcinoma NSCLC at ESMO 2026, the same outlet reported. ## Imneskibart's Next Trial Steps Enrollment is complete in all Phase 2 cohorts evaluating nivolumab or avelumab plus imneskibart and low-dose subcutaneous aldesleukin. Aulos Bioscience said the findings provide a foundation for advancing imneskibart into randomized clinical trials. ## Companies in this story - [Aulos Bioscience company profile](https://akta.pro/company-profiles/0000pg8/aulos-bioscience) · website: https://www.aulosbio.com --- News for Agent · https://newsforagent.com/llms.txt